JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (6): 835-842.DOI: 10.3969/j.issn.1671-2587.2024.06.020
Previous Articles Next Articles
REN Daoju1, LI Xiaowei2, LI Cuiying1,2
Received:
2024-06-18
Online:
2024-12-20
Published:
2024-12-20
CLC Number:
REN Daoju, LI Xiaowei, LI Cuiying. Advances in Non-invasive Cell-free Fetal DNA Blood Group Testing in Prenatal Diagnosis[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 835-842.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lcsxyjy.com/EN/10.3969/j.issn.1671-2587.2024.06.020
[1] CHITTY L S,KHALIL A,BARRETT A N,et al.Safe,accurate,prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA[J]. Prenat Diagn,2013,33(5):416-423. [2] CHITTY L S,MASON S,BARRETT A N,et al.Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia:next-generation sequencing allows for a safer,more accurate,and comprehensive approach[J]. Prenat Diagn,2015,35(7):656-662. [3] MELLIS R,CHANDLER N,JENKINS L,et al.The role of sonographic phenotyping in delivering an efficient noninvasive prenatal diagnosis service for FGFR3-related skeletal dysplasias[J]. Prenat Diagn,2020,40(7):785-791. [4] MONNI G,IUCULANO A.Re:ISUOG Practice Guidelines:invasive procedures for prenatal diagnosis[J]. Ultrasound Obstet & Gyne,2017,49(3):414-415. [5] PERGAMENT E,CUCKLE H,ZIMMERMANN B,et al.Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort[J]. Obstet Gynecol,2014,124(2 Pt 1):210-218. [6] SENTILHES L,SALOMON L J,VAYSSIÈRE C. Cell-free DNA analysis for noninvasive examination of trisomy[J]. N Engl J Med,2015,373(26):2581-2582. [7] NORTON M E,WAPNER R J.Cell-free DNA analysis for noninvasive examination of trisomy[J]. N Engl J Med,2015,373(26):2582. [8] LO Y M,CORBETTA N,CHAMBERLAIN P F,et al.Presence of fetal DNA in maternal plasma and serum[J]. Lancet,1997,350(9076):485-487. [9] TAGLAUER E S,WILKINS-HAUG L,BIANCHI D W.Review:cell-free fetal DNA in the maternal circulation as an indication of placental health and disease[J].Placenta,2014,35(Suppl):S64-S68. [10] ALBERRY M,MADDOCKS D,JONES M,et al.Free fetal DNA in maternal plasma in anembryonic pregnancies:confirmation that the origin is the trophoblast[J]. Prenat Diagn,2007,27(5):415-418. [11] FAAS B H,DE LIGT J,JANSSEN I,et al.Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells[J]. Expert Opin Biol Ther,2012,12(Suppl 1):S19-S26. [12] GUPTA A K,HOLZGREVE W,HUPPERTZ B,et al.Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated [13] LUI Y Y,CHIK K W,CHIU R W,et al.Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation[J]. Clin Chem,2002,48(3):421-427. [14] HAGHIAC M,VORA N L,BASU S,et al.Increased death of adipose cells,a path to release cell-free DNA into systemic circulation of obese women[J]. Obesity,2012,20(11):2213-2219. [15] DRURY S,HILL M,CHITTY L S.Cell-free fetal DNA testing for prenatal diagnosis[J]. Adv Clin Chem,2016,76:1-35. [16] LO Y M,TEIN M S,LAU T K,et al.Quantitative analysis of fetal DNA in maternal plasma and serum:implications for noninvasive prenatal diagnosis[J]. Am J Hum Genet,1998,62(4):768-775. [17] LO Y M,HJELM N M,FIDLER C,et al.Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma[J]. N Engl J Med,1998,339(24):1734-1738. [18] HU H,LIU H,PENG C,et al.Clinical experience of non-invasive prenatal chromosomal aneuploidy testing in 190,277 patient samples[J]. Curr Mol Med,2016,16(8):759-766. [19] BARRETT A N,XIONG L,TAN T Z,et al.Measurement of fetal fraction in cell-free DNA from maternal plasma using a panel of insertion/deletion polymorphisms[J]. PLoS One,2017,12(10):e0186771. [20] TSUI N B,JIANG P Y,CHOW K C,et al.High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing[J]. PLoS One,2012,7(10):e48319. [21] QIAO L W,YU B,LIANG Y T,et al. Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing[J]. Am J Obstet Gynecol,2019,221(4):345.e1-345345.e11. [22] BRINKMAN E K,CHEN T,DE HAAS M,et al. Kinetics and fidelity of the repair of Cas9-induced double-strand DNA breaks[J]. Mol Cell,2018,70(5):801-813.e6. [23] KHIER S,LOHAN L. Kinetics of circulating cell-free DNA for biomedical applications:critical appraisal of the literature[J]. Future Sci OA,2018,4(4):FSO295. [24] HARTWIG T S,AMBYE L,SØRENSEN S,et al. Discordant non-invasive prenatal testing (NIPT)-a systematic review[J]. Prenat Diagn,2017,37(6):527-539. [25] WRIGHT D,WRIGHT A,NICOLAIDES K H.A unified approach to risk assessment for fetal aneuploidies[J]. Ultrasound Obstet & Gyne,2015,45(1):48-54. [26] XUE X Y,TEARE M D,HOLEN I,et al.Optimizing the yield and utility of circulating cell-free DNA from plasma and serum[J]. Clin Chim Acta,2009,404(2):100-104. [27] HUNG E C W,CHIU R W K,LO Y M D. Detection of circulating fetal nucleic acids:a review of methods and applications[J]. J Clin Pathol,2009,62(4):308-313. [28] YOKOTA M,TATSUMI N,NATHALANG O,et al.Effects of heparin on polymerase chain reaction for blood white cells[J]. J Clin Lab Anal,1999,13(3):133-140. [29] NORTON S E,LUNA K K,LECHNER J M,et al.A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device[J]. J Clin Lab Anal,2013,27(4):305-311. [30] NORTON S E,LECHNER J M,WILLIAMS T,et al.A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR[J]. Clin Biochem,2013,46(15):1561-1565. [31] TRIGG R M,MARTINSON L J,PARPART-LI S,et al.Factors that influence quality and yield of circulating-free DNA:a systematic review of the methodology literature[J]. Heliyon,2018,4(7):e00699. [32] PARPART-LI S,BARTLETT B,POPOLI M,et al.The effect of preservative and temperature on the analysis of circulating tumor DNA[J]. Clin Cancer Res,2017,23(10):2471-2477. [33] WONG F C,SUN K,JIANG P Y,et al.Cell-free DNA in maternal plasma and serum:a comparison of quantity,quality and tissue origin using genomic and epigenomic approaches[J]. Clin Biochem,2016,49(18):1379-1386. [34] VALLÉE A,MARCQ M,BIZIEUX A,et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients[J]. Lung Cancer,2013,82(2):373-374. [35] REPISKÁ G,KONEČNÁ B,SHELKE G V,et al. Is the DNA of placental origin packaged in exosomes isolated from plasma and serum of pregnant women?[J]. Clin Chem Lab Med,2018,56(6):e150-e153. [36] PAGE K,HAVA N,WARD B,et al.Detection of HER2 amplification in circulating free DNA in patients with breast cancer[J]. Br J Cancer,2011,104(8):1342-1348. [37] SHERWOOD J L,CORCORAN C,BROWN H,et al.Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC)[J]. PLoS One,2016,11(2):e0150197. [38] KINNINGS S L,GEIS J A,ALMASRI E,et al.Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing[J]. Prenat Diagn,2015,35(8):816-822. [39] ASHOOR G,SYNGELAKI A,POON L C Y,et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation:relation to maternal and fetal characteristics[J]. Ultrasound Obstet & Gyne,2013,41(1):26-32. [40] WANG E,BATEY A,STRUBLE C,et al.Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma[J]. Prenat Diagn,2013,33(7):662-666. [41] ZHOU Y,ZHU Z Y,GAO Y,et al.Effects of maternal and fetal characteristics on cell-free fetal DNA fraction in maternal plasma[J]. Reprod Sci,2015,22(11):1429-1435. [42] CANICK J A,PALOMAKI G E,KLOZA E M,et al.The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies[J]. Prenat Diagn,2013,33(7):667-674. [43] HEDRIANA H,MARTIN K,SALTZMAN D,et al.Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening[J]. Prenat Diagn,2020,40(2):179-184. [44] HUI L,BETHUNE M,WEEKS A,et al.Repeated failed non-invasive prenatal testing owing to low cell-free fetal DNA fraction and increased variance in a woman with severe autoimmune disease[J]. Ultrasound Obstet Gynecol,2014,44(2):242-243. [45] HUI C Y,TAN W C,TAN E L,et al.Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome:lessons learnt[J]. BMJ Case Rep,2016,2016:bcr2016216593. [46] BURNS W,KOELPER N,BARBERIO A,et al.The association between anticoagulation therapy,maternal characteristics,and a failed cfDNA test due to a low fetal fraction[J]. Prenat Diagn,2017,37(11):1125-1129. [47] MA G C,WU W J,LEE M H,et al.Low-molecular-weight heparin associated with reduced fetal fraction and subsequent false-negative cell-free DNA test result for trisomy 21[J]. Ultrasound Obstet Gynecol,2018,51(2):276-277. [48] CANICK J A,KLOZA E M,LAMBERT-MESSERLIAN G M,et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations[J]. Prenat Diagn,2012,32(8):730-734. [49] HAHN S,RUSTERHOLZ C,HÖSLI I,et al. Cell-free nucleic acids as potential markers for preeclampsia[J]. Placenta,2011,32(Suppl):S17-S20. [50] KNIGHT M,REDMAN C W,LINTON E A,et al.Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies[J]. Br J Obstet Gynaecol,1998,105(6):632-640. [51] RAVA R P,SRINIVASAN A,SEHNERT A J,et al.Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X[J]. Clin Chem,2014,60(1):243-250. [52] JORGEZ C J,BISCHOFF F Z.Improving enrichment of circulating fetal DNA for genetic testing:size fractionation followed by whole gene amplification[J]. Fetal Diagn Ther,2009,25(3):314-319. [53] LI Y,ZIMMERMANN B,RUSTERHOLZ C,et al.Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms[J]. Clin Chem,2004,50(6):1002-1011. [54] HELLWIG S,NIX D A,GLIGORICH K M,et al.Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing[J]. PLoS One,2018,13(7):e0197333. [55] HAHN T,DRESE K S,O'SULLIVAN C K. Microsystem for isolation of fetal DNA from maternal plasma by preparative size separation[J]. Clin Chem,2009,55(12):2144-2152. [56] YANG Q W,DU Z W,SONG Y,et al.Size-selective separation and overall-amplification of cell-free fetal DNA fragments using PCR-based enrichment[J]. Sci Rep,2017,7:40936. [57] LIU L L,GUO Z L,HUANG Z Z,et al.Size-selective separation of DNA fragments by using lysine-functionalized silica particles[J]. Sci Rep,2016,6:22029. [58] HU P,LIANG D,CHEN Y Y,et al.An enrichment method to increase cell-free fetal DNA fraction and significantly reduce false negatives and test failures for non-invasive prenatal screening:a feasibility study[J]. J Transl Med,2019,17(1):124. [59] ZENG W,ZHU J J,QI H,et al.Comparison of two superparamagnetic purification magnetic beads-based screening and enrichment techniques for isolating cell-free fetal DNA from maternal plasma for non-invasive prenatal screening[J]. Chin J Med Genet,2024,41(7):797-802. [60] SCHIMANSKI B,KRÄUCHI R,STETTLER J,et al.Fetal [61] PARDI C,HELLBERG Å,ISAKSON P.Single-exon fetal RHD genotyping:a 31-month follow up in the obstetric population of Western Sweden[J]. Trasfusione Del Sangue,2024. [62] SONG W Q,ZHOU S H,SHAO L N,et al.Non-invasive fetal ABO genotyping in maternal plasma using real-time PCR[J]. Clin Chem Lab Med,2015,53(12):1943-1950. [63] RIENECK K,EGEBERG HOTHER C,CLAUSEN F,et al.Next generation sequencing-based fetal ABO blood group prediction by analysis of cell-free DNA from maternal plasma[J]. Transfus Med Hemother,2020,47(1):45-53. [64] O’BRIEN H,HYLAND C,SCHOEMAN E,et al. Non-invasive prenatal testing (NIPT) for fetal Kell,Duffy and Rh blood group antigen prediction in alloimmunised pregnant women:power of droplet digital PCR[J]. Br J Haematol,2020,189(3):e90-e94. [65] CROWTHER C,MIDDLETON P. Anti-D administration after childbirth for preventing [66] CLAUSEN F B,DAMKJÆR M B,DZIEGIEL M H. Noninvasive fetal RhD genotyping[J]. Transfus Apher Sci,2014,50(2):154-162. [67] CLAUSEN F B.Lessons learned from the implementation of non-invasive fetal RHD screening[J]. Expert Rev Mol Diagn,2018,18(5):423-431. [68] BILLS V L,SOOTHILL P W.Fetal blood grouping using cell free DNA-An improved service for RhD negative pregnant women[J]. Transfus Apher Sci,2014,50(2):148-153. [69] KENT J,FARRELL A M,SOOTHILL P.Routine administration of Anti-D:the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice[J]. BMC Pregnancy Childbirth,2014,14:87. [70] DANIELS G,VAN DER SCHOOT C E,OLSSON M L. Report of the fourth International Workshop on molecular blood group genotyping[J]. Vox Sang,2011,101(4):327-332. [71] DE HAAS M,THURIK F F,VAN DER PLOEG C P,et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis:prospective cohort study of a nationwide programme in the Netherlands[J]. BMJ,2016,355:i5789. [72] CLAUSEN F B,CHRISTIANSEN M,STEFFENSEN R,et al.Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis[J]. Transfusion,2012,52(4):752-758. [73] HAIMILA K,SULIN,KUOSMANEN M,et al.Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland[J]. Acta Obstet Gynecol Scand,2017,96(10):1228-1233. [74] CHITTY L S,FINNING K,WADE A,et al.Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation:population based cohort study[J]. BMJ,2014,349:g5243. [75] LE PICHON J B,RIORDAN S M,WATCHKO J,et al. The neurological sequelae of neonatal hyperbilirubinemia:definitions,diagnosis and treatment of the kernicterus spectrum disorders (KSDs)[J]. Curr Pediatr Rev,2017,13(3):199-209. [76] DELANEY M,MATTHEWS D C.Hemolytic disease of the fetus and newborn:managing the mother,fetus,and newborn[J]. Hematology Am Soc Hematol Educ Program,2015,2015:146-151. [77] ZIPRIN J H,PAYNE E,HAMIDI L,et al.ABO incompatibility due to immunoglobulin G anti-B antibodies presenting with severe fetal anaemia[J]. Transfus Med,2005,15(1):57-60. [78] DZIEGIEL M H,KROG G R,HANSEN A T,et al.Laboratory monitoring of mother,fetus,and newborn in hemolytic disease of fetus and newborn[J]. Transfus Med Hemother,2021,48(5):306-315. [79] DONNEBORG M L,HANSEN B M,VANDBORG P K,et al.Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000—2015[J]. J Perinatol,2020,40(2):194-202. [80] MARI G,DETER R L,CARPENTER R L,et al.Noninvasive diagnosis by Doppler ultrasonography of fetal [81] ZIMMERMAN R,CARPENTER R J Jr,DURIG P,et al. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation:a prospective multicentre trial with intention-to-treat[J]. BJOG,2002,109(7):746-752. [82] RIENECK K.Cell-free DNA and next-generation sequencing for prenatal diagnosis[J]. Methods Mol Biol,2024,2753:583-609. |
[1] | ZHUANG Yuan, YU Yang. Strengthening the Application of Centrifugal Technology and Establishing a Combined Apheresis/Blood Purification System in the Department of Transfusion Medicine [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 721-725. |
[2] | LIU Xiaomin, ZHUANG Yuan, YU Yang. Survey Report on Current Status of Transfusion Therapy in Transfusion Medicine Departments of Medical Institutions Across China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 740-743. |
[3] | SHEN Qianyun, CHENG Wenguo, HOU Shuning, YAO Genghong. Differential Expression and Clinical Significance of Vascular Cell Adhesion Molecule-1 in Plasma of Neonates with ABO Hemolytic Disease [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 744-749. |
[4] | WANG Danting, LONG Honghui, NIU Yingying, HUANG Chunyan. Analysis and Clinical Significance of Minor Cross-match Incompatibility with Micro-column Gel Test [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 750-754. |
[5] | CHE Yang, LIU Zheng, ZHOU Xiaoyu. Retrospective Analysis of the Efficacy of Postoperative Plasma Transfusion in Patients with Primary Liver Cancer Undergoing Liver Resection [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 755-761. |
[6] | ZHENG Yan, WANG Wenting, YANG Longfei, WANG Qiong, MU Shijie. Serological Characteristics and DNA Sequence Analysis of Patients with RhD Variant [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 762-765. |
[7] | LIANG Chunyan, DUAN Li, LIU Youying, LIU Fangjiu. Risk Factors and Predictive Models of Transfusion-associated Circulatory Overload in Hospitalized Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 771-776. |
[8] | CAI Yin, CHEN Zhiying, JIANG Ling, REN Yana, ZHENG Lan, ZHOU Guoping. Screening Analysis of HLA Antibodies of Blood Donors in Shanghai Area [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 777-780. |
[9] | GUO Rui, HOU Yun, SU Changshan, et al. Assessing the Residual Risk of Hepatitis B Virus Transmission via Blood Transfusion in 21 Chinese Blood Centers from 2018 to 2022 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 781-786. |
[10] | LI Yan, ZHOU Liling, MA Zhaoze, ZHU Kaijie, WANG Chenlong. Genotypic Identification and Sequence Analysis of B/AB Subtypes in 25 Cases [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 787-791. |
[11] | LI Xin, YANG Junhong. Meta Analysis of Incidence of Platelet Antibody in Pregnant Women in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 805-811. |
[12] | MING Jing, DING Kaiyang, HU Maogui, WANG Xinchen. Efficacy of Avatrombopag Combined with rhTPO for Thrombocytopenia Treatment in Patients with Hematologic Malignancies after Autologous Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 812-817. |
[13] | WANG Jiaqi, XIAO Jun, LI Cuiying. Research Progress of mTOR Pathway in Regulating Self-renewal and Differentiation of Hematopoietic Stem Cells [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 818-824. |
[14] | WANG Shujun, LI Zhaojie, YANG Yi, LUAN Jianfeng. Platelet-derived Products in Wound Healing [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 825-834. |
[15] | . [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 843-848. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||